WOUND HEALING, IN-VITRO AND IN-VIVO ANTI STAPHYLOCOCCUS AUREUS ACTIVITIES OF LIBYAN MYRTUS COMMUNIS L.
Salwa I. Eltawaty*, Muna A. E. Mohammed, Amal S. M. Oteer, Sanaa. O. Yagoub, Aisha Z. Almagboul, Mohamed-Elfatih A. Omare and Asma Alramli
ABSTRACT
With take in consideration the varied medicinal value of medicinal plants (due to a different environmental condition) and the infection complications in general and wound healing retardation in specific, this study aimed to evaluate the Wound healing, In-vitro and In-vivo anti Staphylococcus aureus activities of Libyan Myrtus communis L. Methods: Standard methods and designed animal models were used to achieve the study aim. Results: The result proved that leaves of the Libyan Myrtus communis constitute polar compounds showed in-vitro active growth inhibition zones against standard Staphylococcus aureus ATCC23925 (22mm± 1.06 with MIC of 6.25mg, n=3) as well as the clinical MRSA isolates (25mm± 6, n=31). In wound healing activity assay and with Post Hoc analysis, high significant differences in performance (P value ≤ 01) were shown in treatment days between control and tested groups, where results showed that Myrtus communis enhances the wound healing process by reducing healing period from 12 to 8 days compared to control group. In addition, in the in vivo study, Myrtus ointment actively treated wounds infected with Staphylococcus aureus in 8 days compared with 7 days along with Fucidin ointment. Conclusion: This study suggests that Libyan Myrtus communis is promising as wound healing accelerator and powerful anti-Staphylococcus aureus agent and introduces it as an alternative to Beta-lactam antibiotics and also to Gentamicin and Ciprofloxacin concerning to their side effects after deep clinical evaluation to assess its safety.
Keywords: Wound healing, MRSA, In-vitro, In-vivo antibacterial activity, Myrtus communis.
[Full Text Article]
[Download Certificate]
Impact Factor : 8.181 
